Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say

Executive Summary

Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.

You may also be interested in...



Accelerated Approval Could Expand As Alternative To Progressive Approval

CDER Director Woodcock says agency should issue internal and external guidance to promote consistent use of the pathway.

Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost

Tentative agreement closely resembles FDA's original proposal.

Biosimilar User Fee Negotiations Hit Snag With GPhA Gambit For Lower Fees

The Generic Pharmaceutical Association is balking at continuing to negotiate the design of a biosimilar user fee program that is independent of other user fees and has its own baseline appropriations trigger.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel